Pipeline Overview
Click to learn about the trilaciclib mechanism of action
G1 is advancing its lead clinical compound trilaciclib, a first-in-class therapy designed to improve outcomes for patients who are treated with chemotherapy, in clinical trials assessing myeloprotection and anti-tumor efficacy endpoints in a variety of tumors including colorectal cancer (CRC), breast cancer, and bladder cancer. We are also assessing trilaciclib in two Phase 2 trials: (1) to further examine its mechanism of action in the tumor microenvironment, (2) in combination with an antibody-drug conjugate (ADC).
The safety and efficacy of investigational agents or an investigational use of an approved product have not been established or approved by the FDA or other regulatory authorities.